PlK3CA is implicated as an oncogene in ovarian cancer

Laleh Shayesteh, Yiling Lu, Wen Lin Kuo, Russell Baldocchi, Tony Godfrey, Colin Collins, Daniel Pinkel, Bethan Powell, Gordon Mills, Joe Gray

Research output: Contribution to journalArticle

968 Citations (Scopus)

Abstract

Ovarian cancer is the leading cause of death from gynecological malignancy and the fourth leading cause of cancer death among American women, yet little is known about its molecular aetiology. Studies using comparative genomic hybridization (CGH) have revealed several regions of recurrent, abnormal, DNA sequence copy number that may encode genes involved in the genesis or progression of the disease. One region at 3q26 found to be increased in copy number in approximately 40% of ovarian and others cancers contains PlK3CA, which encodes the p110α catalytic subunit of phosphatidylinositol 3-kinase (Pl3-kinase). The association between PlK3CA copy number and Pl3-kinase activity makes PlK3CA a candidate oncogene because a broad range of cancer-related functions have been associated with Pl3- kinase mediated signalling. These include proliferation, glucose transport and catabolism, cell adhesion, apoptosis, RAS signalling and oncogenic transformation. In addition, downstream effectors of Pl3-kinase, AKT1 and AKT2, have been found to be amplified or activated in human tumours, including ovarian cancer. We show here that PlK3CA is frequently increased in copy number in ovarian cancers, that the increased copy number is associated with increased PlK3CA transcription, p110α protein expression and Pl3- kinase activity and that treatment with the Pl3-kinase inhibitor LY294002 decreases proliferation and increases apoptosis. Our observations suggest PlK3CA is an oncogene that has an important role in ovarian cancer.

Original languageEnglish (US)
Pages (from-to)99-102
Number of pages4
JournalNature Genetics
Volume21
Issue number1
DOIs
StatePublished - Jan 1999
Externally publishedYes

Fingerprint

Phosphatidylinositol 3-Kinase
Oncogenes
Ovarian Neoplasms
Cause of Death
Neoplasms
Phosphotransferases
Apoptosis
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one
Comparative Genomic Hybridization
Cell Adhesion
Disease Progression
Catalytic Domain
Glucose
Genes
Proteins

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)

Cite this

Shayesteh, L., Lu, Y., Kuo, W. L., Baldocchi, R., Godfrey, T., Collins, C., ... Gray, J. (1999). PlK3CA is implicated as an oncogene in ovarian cancer. Nature Genetics, 21(1), 99-102. https://doi.org/10.1038/5042

PlK3CA is implicated as an oncogene in ovarian cancer. / Shayesteh, Laleh; Lu, Yiling; Kuo, Wen Lin; Baldocchi, Russell; Godfrey, Tony; Collins, Colin; Pinkel, Daniel; Powell, Bethan; Mills, Gordon; Gray, Joe.

In: Nature Genetics, Vol. 21, No. 1, 01.1999, p. 99-102.

Research output: Contribution to journalArticle

Shayesteh, L, Lu, Y, Kuo, WL, Baldocchi, R, Godfrey, T, Collins, C, Pinkel, D, Powell, B, Mills, G & Gray, J 1999, 'PlK3CA is implicated as an oncogene in ovarian cancer', Nature Genetics, vol. 21, no. 1, pp. 99-102. https://doi.org/10.1038/5042
Shayesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, Collins C et al. PlK3CA is implicated as an oncogene in ovarian cancer. Nature Genetics. 1999 Jan;21(1):99-102. https://doi.org/10.1038/5042
Shayesteh, Laleh ; Lu, Yiling ; Kuo, Wen Lin ; Baldocchi, Russell ; Godfrey, Tony ; Collins, Colin ; Pinkel, Daniel ; Powell, Bethan ; Mills, Gordon ; Gray, Joe. / PlK3CA is implicated as an oncogene in ovarian cancer. In: Nature Genetics. 1999 ; Vol. 21, No. 1. pp. 99-102.
@article{10ddfa7916d34b63b116bd66d65c6ef4,
title = "PlK3CA is implicated as an oncogene in ovarian cancer",
abstract = "Ovarian cancer is the leading cause of death from gynecological malignancy and the fourth leading cause of cancer death among American women, yet little is known about its molecular aetiology. Studies using comparative genomic hybridization (CGH) have revealed several regions of recurrent, abnormal, DNA sequence copy number that may encode genes involved in the genesis or progression of the disease. One region at 3q26 found to be increased in copy number in approximately 40{\%} of ovarian and others cancers contains PlK3CA, which encodes the p110α catalytic subunit of phosphatidylinositol 3-kinase (Pl3-kinase). The association between PlK3CA copy number and Pl3-kinase activity makes PlK3CA a candidate oncogene because a broad range of cancer-related functions have been associated with Pl3- kinase mediated signalling. These include proliferation, glucose transport and catabolism, cell adhesion, apoptosis, RAS signalling and oncogenic transformation. In addition, downstream effectors of Pl3-kinase, AKT1 and AKT2, have been found to be amplified or activated in human tumours, including ovarian cancer. We show here that PlK3CA is frequently increased in copy number in ovarian cancers, that the increased copy number is associated with increased PlK3CA transcription, p110α protein expression and Pl3- kinase activity and that treatment with the Pl3-kinase inhibitor LY294002 decreases proliferation and increases apoptosis. Our observations suggest PlK3CA is an oncogene that has an important role in ovarian cancer.",
author = "Laleh Shayesteh and Yiling Lu and Kuo, {Wen Lin} and Russell Baldocchi and Tony Godfrey and Colin Collins and Daniel Pinkel and Bethan Powell and Gordon Mills and Joe Gray",
year = "1999",
month = "1",
doi = "10.1038/5042",
language = "English (US)",
volume = "21",
pages = "99--102",
journal = "Nature Genetics",
issn = "1061-4036",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - PlK3CA is implicated as an oncogene in ovarian cancer

AU - Shayesteh, Laleh

AU - Lu, Yiling

AU - Kuo, Wen Lin

AU - Baldocchi, Russell

AU - Godfrey, Tony

AU - Collins, Colin

AU - Pinkel, Daniel

AU - Powell, Bethan

AU - Mills, Gordon

AU - Gray, Joe

PY - 1999/1

Y1 - 1999/1

N2 - Ovarian cancer is the leading cause of death from gynecological malignancy and the fourth leading cause of cancer death among American women, yet little is known about its molecular aetiology. Studies using comparative genomic hybridization (CGH) have revealed several regions of recurrent, abnormal, DNA sequence copy number that may encode genes involved in the genesis or progression of the disease. One region at 3q26 found to be increased in copy number in approximately 40% of ovarian and others cancers contains PlK3CA, which encodes the p110α catalytic subunit of phosphatidylinositol 3-kinase (Pl3-kinase). The association between PlK3CA copy number and Pl3-kinase activity makes PlK3CA a candidate oncogene because a broad range of cancer-related functions have been associated with Pl3- kinase mediated signalling. These include proliferation, glucose transport and catabolism, cell adhesion, apoptosis, RAS signalling and oncogenic transformation. In addition, downstream effectors of Pl3-kinase, AKT1 and AKT2, have been found to be amplified or activated in human tumours, including ovarian cancer. We show here that PlK3CA is frequently increased in copy number in ovarian cancers, that the increased copy number is associated with increased PlK3CA transcription, p110α protein expression and Pl3- kinase activity and that treatment with the Pl3-kinase inhibitor LY294002 decreases proliferation and increases apoptosis. Our observations suggest PlK3CA is an oncogene that has an important role in ovarian cancer.

AB - Ovarian cancer is the leading cause of death from gynecological malignancy and the fourth leading cause of cancer death among American women, yet little is known about its molecular aetiology. Studies using comparative genomic hybridization (CGH) have revealed several regions of recurrent, abnormal, DNA sequence copy number that may encode genes involved in the genesis or progression of the disease. One region at 3q26 found to be increased in copy number in approximately 40% of ovarian and others cancers contains PlK3CA, which encodes the p110α catalytic subunit of phosphatidylinositol 3-kinase (Pl3-kinase). The association between PlK3CA copy number and Pl3-kinase activity makes PlK3CA a candidate oncogene because a broad range of cancer-related functions have been associated with Pl3- kinase mediated signalling. These include proliferation, glucose transport and catabolism, cell adhesion, apoptosis, RAS signalling and oncogenic transformation. In addition, downstream effectors of Pl3-kinase, AKT1 and AKT2, have been found to be amplified or activated in human tumours, including ovarian cancer. We show here that PlK3CA is frequently increased in copy number in ovarian cancers, that the increased copy number is associated with increased PlK3CA transcription, p110α protein expression and Pl3- kinase activity and that treatment with the Pl3-kinase inhibitor LY294002 decreases proliferation and increases apoptosis. Our observations suggest PlK3CA is an oncogene that has an important role in ovarian cancer.

UR - http://www.scopus.com/inward/record.url?scp=0032590011&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032590011&partnerID=8YFLogxK

U2 - 10.1038/5042

DO - 10.1038/5042

M3 - Article

C2 - 9916799

AN - SCOPUS:0032590011

VL - 21

SP - 99

EP - 102

JO - Nature Genetics

JF - Nature Genetics

SN - 1061-4036

IS - 1

ER -